Search research articles
Contact Us
Filters
Showing results (261-270 of 418) with videos related to
Page
of 42
Sort By:
European Urology
|
May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun, Lorenzo Marconi, Tim Eisen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Helen Dearden, Lewis Au, Daniel Y Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
The Lancet. Gastroenterology & Hepatology
|
June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
Nick Powell, Hajir Ibraheim, Tim Raine, et al.
British Journal of Cancer
|
March 22, 2017
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, et al.
BMC Cancer
|
November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Hannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Viktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
The Journal of Pathology
|
October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
Marco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.
Cancer Discovery
|
May 2, 2025
MANIFEST: Multiomic Platform for Cancer Immunotherapy
Kok Haw Jonathan Lim, Zayd Tippu, Pippa G Corrie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Page
of 42
Search research articles
Search
Showing results (261-270 of 418) with videos related to
Sort By:
Page
of 42
European Urology
|
May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun, Lorenzo Marconi, Tim Eisen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Helen Dearden, Lewis Au, Daniel Y Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
The Lancet. Gastroenterology & Hepatology
|
June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
Nick Powell, Hajir Ibraheim, Tim Raine, et al.
British Journal of Cancer
|
March 22, 2017
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, et al.
BMC Cancer
|
November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Hannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Viktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
The Journal of Pathology
|
October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
Marco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.
Cancer Discovery
|
May 2, 2025
MANIFEST: Multiomic Platform for Cancer Immunotherapy
Kok Haw Jonathan Lim, Zayd Tippu, Pippa G Corrie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Page
of 42